Boule Diagnostics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Boule Diagnostics's earnings have been declining at an average annual rate of -21.9%, while the Medical Equipment industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 6.1% per year.
Anahtar bilgiler
-21.9%
Kazanç büyüme oranı
-17.1%
EPS büyüme oranı
Medical Equipment Sektör Büyümesi | 6.2% |
Gelir büyüme oranı | 6.1% |
Özkaynak getirisi | -83.4% |
Net Marj | -37.7% |
Sonraki Kazanç Güncellemesi | 11 Feb 2025 |
Yakın geçmiş performans güncellemeleri
Recent updates
Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?
Oct 10Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Jul 25Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal
Jul 24Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)
Jun 06Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Jul 25Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 26Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals
Jul 26Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)
Jul 19We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Feb 03The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing
Apr 29Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?
Apr 09Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Mar 25Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend
Mar 07Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?
Feb 17These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively
Jan 30Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?
Jan 14How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?
Dec 28Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Dec 10What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?
Nov 22Gelir ve Gider Dağılımı
Boule Diagnostics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 563 | -213 | 164 | 310 |
30 Jun 24 | 573 | 21 | 162 | 49 |
31 Mar 24 | 576 | 27 | 155 | 48 |
31 Dec 23 | 571 | 25 | 153 | 53 |
30 Sep 23 | 572 | 19 | 149 | 52 |
30 Jun 23 | 558 | 17 | 148 | 50 |
31 Mar 23 | 559 | 16 | 146 | 53 |
31 Dec 22 | 548 | 13 | 144 | 52 |
30 Sep 22 | 539 | 27 | 138 | 50 |
30 Jun 22 | 525 | 32 | 131 | 48 |
31 Mar 22 | 495 | 28 | 126 | 45 |
31 Dec 21 | 463 | 23 | 120 | 43 |
30 Sep 21 | 416 | -27 | 115 | 42 |
30 Jun 21 | 403 | -13 | 113 | 42 |
31 Mar 21 | 383 | -55 | 107 | 44 |
31 Dec 20 | 400 | -48 | 111 | 43 |
30 Sep 20 | 437 | -8 | 116 | 41 |
30 Jun 20 | 470 | -8 | 119 | 37 |
31 Mar 20 | 499 | 35 | 130 | 32 |
31 Dec 19 | 499 | 38 | 128 | 30 |
30 Sep 19 | 476 | 32 | 126 | 31 |
30 Jun 19 | 456 | 21 | 124 | 33 |
31 Mar 19 | 444 | 36 | 115 | 33 |
31 Dec 18 | 424 | 41 | 110 | 29 |
30 Sep 18 | 425 | 48 | 111 | 24 |
30 Jun 18 | 424 | 60 | 112 | 25 |
31 Mar 18 | 421 | 43 | 111 | 27 |
31 Dec 17 | 428 | 37 | 116 | 32 |
30 Sep 17 | 422 | 31 | 114 | 38 |
30 Jun 17 | 421 | 28 | 110 | 38 |
31 Mar 17 | 419 | 38 | 109 | 38 |
31 Dec 16 | 397 | 36 | 105 | 37 |
30 Sep 16 | 383 | 36 | 97 | 40 |
30 Jun 16 | 364 | 22 | 96 | 42 |
31 Mar 16 | 341 | 15 | 93 | 42 |
31 Dec 15 | 331 | 15 | 89 | 40 |
30 Sep 15 | 333 | 29 | 95 | 31 |
30 Jun 15 | 318 | 33 | 91 | 26 |
31 Mar 15 | 309 | 33 | 89 | 23 |
31 Dec 14 | 307 | 30 | 88 | 24 |
30 Sep 14 | 289 | 14 | 83 | 24 |
30 Jun 14 | 285 | -68 | 83 | 25 |
31 Mar 14 | 287 | -64 | 84 | 24 |
31 Dec 13 | 277 | -70 | 84 | 24 |
Kaliteli Kazançlar: BOUL is currently unprofitable.
Büyüyen Kar Marjı: BOUL is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BOUL is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Büyüme Hızlandırma: Unable to compare BOUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: BOUL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Özkaynak Getirisi
Yüksek ROE: BOUL has a negative Return on Equity (-83.38%), as it is currently unprofitable.